ADIAL PHARMACEUTICALS, INC. 8-K

What Happened
Adial Pharmaceuticals, Inc. announced on March 6, 2026 that it issued a press release containing financial information for its fiscal year ended December 31, 2025. The press release was attached to the Form 8-K as Exhibit 99.1 and is incorporated by reference under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Filing date: March 6, 2026 (Form 8-K, Item 2.02).
• Period covered: fiscal year ended December 31, 2025.
• Disclosure format: press release attached as Exhibit 99.1 to the 8-K.
• The 8-K reports results of operations and financial condition (no other substantive items such as executive changes were reported in this filing).

Why It Matters
This 8-K is the company’s timely disclosure that it has released FY2025 earnings and related financial information. Investors should review the attached press release for specifics on revenue, net income (or loss), cash position, and any management commentary, since those figures directly affect valuation and trading decisions. Because the 8-K attaches a press release rather than filing full audited statements or extended commentary, investors may also want to look for subsequent filings (e.g., 10-K or quarterly reports) for audited financials and more detailed discussion.